Society for Endocrinology guidelines for the diagnosis and management of post-bariatric hypoglycaemia
- PMID: 38451861
- PMCID: PMC11046333
- DOI: 10.1530/EC-23-0285
Society for Endocrinology guidelines for the diagnosis and management of post-bariatric hypoglycaemia
Abstract
Post bariatric hypoglycaemia (PBH) is typically a post-prandial hypoglycaemia occurring about 2-4 hours after eating in people who have undergone bariatric surgery. PBH develops relatively late after surgery and often after discharge from post-surgical follow-up by bariatric teams, leading to variability in diagnosis and management in non-specialist centres.
Aim: to improve and standardise clinical practice in the diagnosis and management of PBH.
Objectives: (1) to undertake an up-to-date review of the current literature; (2) to formulate practical and evidence-based guidance with regards on the diagnosis and treatment of PBH; (3) to recommend future avenues for research in this condition.
Method: A scoping review was undertaken after an extensive literature search. A consensus on the guidance and confidence in the recommendations was reached by the steering group authors prior to review by key stakeholders.
Outcome: We make pragmatic recommendations for the practical diagnosis and management of PBH including criteria for diagnosis and recognition, as well as recommendations for research areas that should be explored.
Conflict of interest statement
T.M-M.T. declares that she is a shareholder in and consultant for Zihipp Ltd. B.K., C.B.L., G.A.B., R.A., S.P. and K.M. declare no conflicts of interest. S.A. declares consultancy fees for educational events from Johnson & Johnson. J.H. and K.McC. declare honoraria for speaking engagements and advisory work for Novo Nordisk. B.McG. declares that she is a shareholder in Reset Health, a research grant from Novo Nordisk, honoraria for advisory work for Novo Nordisk, Pfizer, Johnson & Johnson, Boehringer Ingleheim, and consultancy fees for educational events from Novo Nordisk, Lilly, Amgen, Astra Zeneca, Sanofi and Johnson & Johnson. S.F. collaborates with and receives funding from Novo Nordisk (Cell Therapy Programme). G.K.D. has received research grants from Novo Nordisk and DDM, as well as honoraria for lectures, presentations, speaker’s bureaus, manuscript writing and educational events from Novo Nordisk, Johnson & Johnson/Ethicon and Medtronic. R.L.B. reports honoraria from Novo Nordisk, Eli Lilly, Medscape, and ViiV Healthcare Ltd., and advisory board and consultancy work for Novo Nordisk, Eli Lilly, Pfizer, Gila Therapeutics Ltd., Epitomee Medical Ltd. and ViiV Healthcare Ltd., and from May 2023 is an employee and shareholder of Eli Lilly and Company.
Figures
References
-
- Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, et al.American Association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocrine Practice 202228528–562. (10.1016/j.eprac.2022.03.010) - DOI - PubMed
-
- Vanderveen KA Grant CS Thompson GB Farley DR Richards ML Vella A Vollrath B & Service FJ. Outcomes and quality of life after partial pancreatectomy for noninsulinoma pancreatogenous hypoglycemia from diffuse islet cell disease. Surgery 20101481237–1245. (10.1016/j.surg.2010.09.027) - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
